Fundraising Fox

Volitionrx

NYSE: VNRX

Henderson, US · Delaware corporation

Find your way into Volitionrx

39 people in our graph share verified history with the Volitionrx team — schools, employers, funds. One of them is your warm intro.

Martin Gouldstoneunlockedknows Mark Eccleston · together at VALIRX PLC (overlapped)

×2knows the team · via Cambridge University

×8knows the team · via University of Dundee

knows the team · via Aston University

Volition develops Nu.Q epigenetics-based blood tests that detect nucleosome changes associated with cancer, sepsis, and other diseases in both humans and animals. Its products include diagnostic assays for NETosis detection, research-use assays, and a canine cancer blood test.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

JM

Jacob MicallefChief Scientific Officer

JM

Jake Micallef

Jake MicallefinChief Scientific Officer

ME

Mark Eccleston

Mark Eccleston inCo-founding ScientistMark Eccleston is a co-founding scientist at VolitionRx who has spent over 13 years developing the company's epigenetics-based blood test technology, serving previously as Chief Technology Officer and Business Development Director, and holds 25 patents related to the platform. He has a background in organic and polymer chemistry with expertise in biodegradable polymers for drug delivery, and through his consultancy OncoLytika has provided scientific and management support to VolitionRx's diagnostic and therapeutic development programs.

TH

Terig Hughes

Terig HughesinChief Financial Officer

ST

Salvatore Thomas ButeraExecutive

RR

Rodney RootsaertExecutive

LB

Louise Batchelor

Louise BatchelorinGroup Chief Marketing & Communications Officer

GF

Gael Forterre

Gael ForterreinChief Commercial Officer (CCO)

GM

Gaetan Michel

Gaetan MichelinChief Operating Officer

JK

Jasmine Kway

Jasmine KwayChief Revenue Officer

DC

David Cecil VanstonChief Financial Officer

JT

Jason Terrell

Jason TerrellinChief Executive Officer of Volition America

Reported raises · per SEC filings

Form D private placements

$52.6M disclosed across 8 rounds · 2014–2025

▶$22.6MraisedJan 2026 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Alan ColmanDirector
Ethel RubinDirector
Terig HughesExecutive Officer
Kim NguyenDirector
Salvatore Thomas ButeraExecutive Officer
Rodney RootsaertExecutive Officer
Louise BatchelorExecutive Officer
Gael ForterreExecutive Officer
Gaetan MichelExecutive Officer
Timothy I StillDirector
Phillip BarnesDirector
Jasmine KwayExecutive Officer
Jacob MicallefExecutive Officer
Guy Archibald InnesDirector
Cameron ReynoldsExecutive Officer, Director
Nicholas PlummerExecutive Officer
Mickie HenshallDirector

Offering amount: $22.6M
Amount sold: $22.6M
First sale: May 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$100KraisedMar 2024 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

RODNEY ROOTSAERTExecutive Officer
JASMINE KWAYExecutive Officer
MARTIN CHARLES FAULKESExecutive Officer, Director
JACOB MICALLEFExecutive Officer
GAEL FORTERREExecutive Officer
TERIG HUGHESExecutive Officer
ALAN COLMANDirector
MICKIE HENSHALLDirector
PHILLIP BARNESDirector
EDWARD FUTCHERDirector
NICHOLAS PLUMMERExecutive Officer
GAETAN MICHELExecutive Officer
LOUISE BATCHELORExecutive Officer
GUY ARCHIBALD INNESDirector
KIM NGUYENDirector
CAMERON REYNOLDSExecutive Officer, Director
SALVATORE THOMAS BUTERAExecutive Officer

Offering amount: $100K
Amount sold: $100K
First sale: Mar 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$24MraisedAug 2018 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Rodney RootsaertExecutive Officer
Habib SkaffDirector
David Cecil VanstonExecutive Officer
Guy Archibald InnesDirector
Martin Charles FaulkesDirector
Jason TerrellExecutive Officer
Cameron ReynoldsExecutive Officer, Director
Edward FutcherDirector
Jacob MicallefExecutive Officer
Alan ColmanDirector

Offering amount: $24M
Amount sold: $24M
First sale: Aug 2018
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$721.8KraisedNov 2014 · 21 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Cameron ReynoldsExecutive Officer, Director
Rodney Gerard RootsaertExecutive Officer
Alan ColmanDirector
Guy Archibold InnesDirector
Martin FaulkesDirector
Habib SkaffDirector
Mike O'ConnellExecutive Officer

Offering amount: $721.8K
Amount sold: $721.8K
Sales commissions: $57K
Placement agents: GVC Capital LLC
First sale: Nov 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$750KraisedOct 2014 · 23 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Martin FaulkesDirector
Cameron ReynoldsExecutive Officer, Director
Guy Archibold InnesDirector
Rodney Gerard RootsaertExecutive Officer
Mike O'ConnellExecutive Officer
Alan ColmanDirector
Habib SkaffDirector

Offering amount: $750K
Amount sold: $750K
Sales commissions: $60K
Placement agents: GVC Capital LLC
First sale: Sep 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$229.4KraisedOct 2014 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Mike O'ConnellExecutive Officer
Rodney Gerard RootsaertExecutive Officer
Guy Archibold InnesDirector
Alan ColmanDirector
Martin FaulkesDirector
Habib SkaffDirector
Cameron ReynoldsExecutive Officer, Director

Offering amount: $229.4K
Amount sold: $229.4K
First sale: Oct 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.2MraisedSep 2014 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Guy Archibold InnesDirector
Cameron ReynoldsExecutive Officer, Director
Rodney Gerard RootsaertExecutive Officer
Mike O'ConnellExecutive Officer
Martin FaulkesDirector
Habib SkaffDirector
Alan ColmanDirector

Offering amount: $1.2M
Amount sold: $1.2M
Sales commissions: $59.9K
Placement agents: "Founding Asset Management (""FAM"")"
First sale: Sep 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3MraisedMar 2014 · 24 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

CAMERON REYNOLDSExecutive Officer, Director
MALCOLM LEWINExecutive Officer
RODNEY GERARD ROOTSAERTExecutive Officer
MARTIN FAULKESDirector
GUY ARCHIBALD INNESDirector
ALAN COLMANDirector

Offering amount: $3M
Amount sold: $3M
Finders' fees: $160K
Placement agents: Founding Asset Management, Lake Street Capital Markets, MZ Advisory Pte Ltd
First sale: Feb 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

IDEXX Laboratories, Inc.56 shared keywordsIDEXX develops diagnostic and software products for veterinary clinics, livestock and dairy operations, and water quality testing. The company serves the global animal health, food safety, and public health sectors with point-of-care and laboratory diagnostic solutions.

Companies competing with Volitionrx for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Volitionrx do?: Volition develops Nu.Q epigenetics-based blood tests that detect nucleosome changes associated with cancer, sepsis, and other diseases in both humans and animals. Its products include diagnostic assays for NETosis detection, research-use assays, and a canine cancer blood test.
Who founded Volitionrx?: Volitionrx was founded by Jacob Micallef, Jake Micallef, Mark Eccleston.
How much funding has Volitionrx raised?: Volitionrx has disclosed $52.6M raised across 8 rounds.
Where is Volitionrx headquartered?: Volitionrx is headquartered in Henderson, US.